Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two

Executive Summary

• Hemostemix Inc. signed a binding Letter of Intent to acquire two leading Dominican Republic interventional cardiology practices for 2,000,000 HEM common shares each, marking the first step in its international clinic roll‑up strategy for ACP‑01 therapy.
• The acquisition provides immediate access to >200 treated patients and establishes a commercial foothold in the Dominican Republic and the Bahamas, with plans to replicate the model in Florida, Puerto Rico, and Canada.
• The TSX Venture Exchange approved an extension of Hemostemix’s non‑brokered private placement until Dec 1, 2025; the offering has so far raised $461,230 from 4,193,000 units at $0.11 per unit, each unit including a common share and a warrant (exercise price $0.15, two‑year term, accelerated expiry provision).

Key Details

• Acquisition Structure – Each cardiology practice will be purchased for 2,000,000 HEM common shares (subject to adjustment and TSXV approval).
• Target Practices – Dr. Roberto Manuel Fernandez‑de‑Castro and Dr. Hector Rosario Figueroa, both highly regarded interventional cardiologists with a combined >200 ACP‑01 patient treatments.
• Clinical Scope – The physicians will continue to treat Angina, Ischemic & Dilated Cardiomyopathy, Congestive Heart Failure, Peripheral Arterial Disease, Chronic Limb‑Threatening Ischemia, and Vascular Dementia, and will aid regulatory approvals in the Dominican Republic.
• Strategic Rationale – Provides a “turnkey profit structure” that integrates clinical care with ACP‑01 commercialization, creating a sustainable patient flow and enabling future trial expansion.
• Future Expansion Plan – Model intended for replication in additional markets (Florida, Puerto Rico, Canada) under various regulatory pathways.

Financing Extension Details

• Extension Approval: TSXV extended the private placement deadline to 1 December 2025.
• Units Issued to Date: 4,193,000 units at $0.11 per unit → gross proceeds $461,230.
• Unit Composition: 1 common share + 1 warrant (exercise price $0.15, two‑year expiry).
• Accelerated Expiry Provision: If the weighted average TSXV price exceeds $0.185 for ten consecutive trading days after four months + 1 day post‑closing, Hemostemix may accelerate warrant expiry to 30 days after a press release.

Notable Quotes

“This acquisition is a transformational milestone for Hemostemix,” said Thomas Smeenk, CEO. “These acquisitions are the first of many, enabling us to focus advertising and patient flow in a regulatory‑compliant manner that is financially rewarding.”